Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020)
Protalix BioTherapeutics' quarterly Notes Payables came in at $4.1 million in Q4 2020, down 5.0% year-on-year from $4.3 million in Q1 2020, and down 4.98% quarter-over-quarter from $4.3 million in Q3 2020.
Protalix BioTherapeutics has reported Notes Payables for 2 years, with the latest figure at $4.1 million in Q4 2020.
- For the quarter ending Q4 2020, Notes Payables fell 5.0% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2020 stood at $4.1 million (down 5.0% YoY), and the FY2020 full-year result was $4.1 million, down 5.0% from the prior year.
- Notes Payables for Q4 2020 stood at $4.1 million, down from $4.3 million in the prior quarter.
- The five-year high for Notes Payables was $4.3 million in Q4 2019, with the low at $4.1 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 4.09 Mn |
| Sep 30, 2020 | 4.30 Mn |
| Jun 30, 2020 | 4.30 Mn |
| Mar 31, 2020 | 4.30 Mn |
| Dec 31, 2019 | 4.30 Mn |